RxDoctor Payments Data

Richard Carney, MD

Internal Medicine · Houston, TXNPI 1124018544

Payments from drug & device makers

$6,777in general payments, 2019–2025

Across 387 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$696
  • Amgen$554
  • Mannkind Corporation$318
  • AbbVie$301
  • Esperion Therapeutics, Inc.$228
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$6,777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,777 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$85,471
Medicare patients
240
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate61$72,639
EliquisApixaban54$50,905
OzempicSemaglutide48$45,332
MounjaroTirzepatide15$17,935
XareltoRivaroxaban13$17,758
Tresiba Flextouch U-100Insulin Degludec17$17,108
SymbicortBudesonide/Formoterol Fumarate25$12,041
MyrbetriqMirabegron14$8,962
Olmesartan Medoxomil276$5,912
Atorvastatin Calcium467$4,708
SynthroidLevothyroxine Sodium69$4,301
Levothyroxine Sodium311$3,941
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,628
Amlodipine Besylate390$3,142
Metoprolol Succinate134$3,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$23$72,63961 claims
PfizerEliquis, Paxlovid$168$52,25265 claims
Novo NordiskOzempic$1,099$45,33248 claims
Lilly USA, LLCMounjaro$696$17,93515 claims
AstraZenecaSymbicort$112$12,04125 claims
Astellas Pharma US IncMyrbetriq$20$8,96214 claims
AbbVieSynthroid$301$4,30169 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$204$3,941311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →